Provided by Tiger Trade Technology Pte. Ltd.

ADC Therapeutics SA

0.9966
+0.03653.80%
Post-market: 0.9900-0.0066-0.66%19:30 EDT
Volume:1.09M
Turnover:1.07M
Market Cap:126.61M
PE:-1.50
High:1.00
Open:0.9740
Low:0.9700
Close:0.9601
52wk High:4.98
52wk Low:0.7796
Shares:127.04M
Float Shares:88.56M
Volume Ratio:0.42
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6636
EPS(LYR):-1.1224
ROE:-705.53%
ROA:-19.57%
PB:-0.55
PE(LYR):-0.89

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 04

ADC Therapeutics SA expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
May 01

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 01

ADC Therapeutics grants options for 49,400 shares to new employees under inducement plan

Reuters
·
May 01

ADC Therapeutics to host first-quarter results conference call and webcast

Reuters
·
Apr 27

ADC Therapeutics announces annual general meeting of shareholders

Reuters
·
Apr 11

Analysts’ Top Healthcare Picks: ADC Therapeutics (ADCT), Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
Apr 09

Redmile Group reports ADC Therapeutics disposal worth $10.1 million

Reuters
·
Apr 03

ADC Therapeutics grants 17,000-share option award under employee inducement plan

Reuters
·
Apr 02

ADC Therapeutics Sa : H.c. Wainwright Raises Target Price to $8 From $7

THOMSON REUTERS
·
Mar 23

U.S. RESEARCH ROUNDUP- ArriVent Biopharma, Aveanna Healthcare Holdings, EQT

Reuters
·
Mar 23

RBC Capital Sticks to Their Buy Rating for ADC Therapeutics (ADCT)

TIPRANKS
·
Mar 12

ADC Therapeutics files to sell 9.83M common shares for holders

TIPRANKS
·
Mar 11

ADC Therapeutics Sa - Selling Shareholders May Offer up to 9,834,776 Common Shares From Time to Time - SEC Filing

THOMSON REUTERS
·
Mar 11

ADC Therapeutics SA reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 10

ADC Therapeutics FY 2025 license revenues and royalties jumped 401% to USD 7.81 million

Reuters
·
Mar 10

Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend

Reuters
·
Mar 10

BRIEF-ADC Therapeutics Q4 Income From Operations USD -17.919 Million Vs. IBES Estimate USD -30.1 Million

Reuters
·
Mar 10

ADC Therapeutics Q4 Operating Expenses USD -40.977 Million

THOMSON REUTERS
·
Mar 10

Press Release: ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

Dow Jones
·
Mar 10